Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors

Journal of Neuro-Oncology

Volumn 93, Issue 2, 2009, Pages 219-228

  Kanamori, Masayuki ^a   Kumabe, Toshihiro ^a   Sonoda, Yukihiko ^a   Nishino, Yoshikazu ^b   Watanabe, Mika ^a   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Dissemination; Ki 67; Nestin; Oligodendroglioma; Predictive factors

Indexed keywords

HERMES ANTIGEN; KI 67 ANTIGEN; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NESTIN; NIMUSTINE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; BRAIN SURGERY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; DISEASE COURSE; DRUG HYPERSENSITIVITY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CHILD; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERMEDIATE FILAMENT PROTEINS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 67349223524     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9762-7     Document Type: Article

References (34)

1. The Committee of Brain Tumor Registry of Japan (2003) Report of brain tumor registry of Japan (1969-1996). Neurol Med Chir Tokyo 43(Suppl):1-111. doi: 10.2176/nmc.43.1
2. Coons SW, Johnson PC, Scheithauer BW et al (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393. doi:10.1002/ (SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W
3. Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279-1291. doi: 10.1097/00006123-199912000-00001
4. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714. doi: 10.1200/ JCO.2005.04.3414
5. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722. doi: 10.1200/JCO.2005.04.6078
6. McLendon RE, Herndon JEII, West B et al (2005) Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 104:1693-1699. doi: 10.1002/cncr.21362
7. Levin N, Lavon I, Zelikovitsh B et al (2006) Progressive low-grade oligodendrogliomas Response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759-1765. doi: 10.1002/cncr.21809
8. Hagel C, Stavrou DK (1999) CD44 expression in primary and recurrent oligodendrogliomas and in adjacent gliotic brain tissue. Neuropathol Appl Neurobiol 25:313-318. doi: 10.1046/j.1365-2990.1999.00181.x
9. Coons SW, Johnson PC, Perl DK (1997) The prognostic significance of Ki-67 labeling indices for oligodendroglioma. Neurosurgery 41:878-885. doi: 10.1097/00006123-199710000-00021
10. Dehghani F, Schachenmayr W, Laun A et al (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases. Acta Neuropathol 95:493-504. doi: 10.1007/s004010050830
11. Strojnik T, Røsland GV, Sakariassen PO et al (2007) Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: Correlation of nestin with prognosis of patient survival. Surg Neurol 68:133-143. doi: 10.1016/j.surneu.2006.10.050
12. Zulewski H, Abraham EJ, Gerlach MJ et al (2001) Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 50:521-533. doi: 10.2337/diabetes.50.3.521
13. Lebrun C, Fontaine D, Bourg V et al (2007) Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391-398. doi: 10.1111/j.1468-1331.2007.01675.x
14. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479-489
15. Parsa AT, Wachhorst S, Lamborn KR et al (2005) Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 102:622-628
16. Grabb PA, Albright AL, Pang D (1992) Dissemination of supratentorial malignant gliomas via cerebrospinal fluid in children. Neurosurgery 30:64-71
17. Kato H, Fujimura M, Kumabe T et al (2004) PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci 11:37-41
18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer Press, Lyon, pp 54-67
19. Ogawa K, Yoshii Y, Toita T et al (2006) Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: A prospective study. Anticancer Res 26:2457-2462
20. Cunningham JM, Kimmel DW, Scheithauer BW et al (1997) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value. J Neurosurg 86:121-130
21. Friedman HS, McLendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857
22. Saito R, Kumabe T, Jokura H et al (2003) Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol 61:227-235
23. Smith JS, Parney IF, Lamborn KR et al (2007) Treatment for posterior fossa dissemination of primary supratentorial glioma. J Neurosurg 106:567-574
24. Khoshyomn S, Lew S, DeMattia J et al (1999) Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression. J Neurooncol 45:111-116
25. Wei LC, Shi M, Cao R, Chen LW et al (2007) Nestin small interfering RNA (siRNA) reduces cell growth in cultured astrocytoma cells. Brain Res 27(1196):103-112
26. Mangiola A, Lama G, Giannitelli C et al (2007) Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: Possible prognostic implications. Clin Cancer Res 13:6970-6977
27. Günther HS, Schmidt NO, Phillips HS et al. (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897-2909
28. Pilkington GJ (1994) Tumor cell migration in the central nervous system. Brain Pathol 4:157-166
29. Weller M, Berger H, Hartmann C et al (2007) Combined 1p/19q loss in oligodendroglial tumors: Predictive or prognostic biomarker? Clin Cancer Res 13:6933-6937
30. Stander M, Peraud A, Leroch B et al (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma. Cancer 101:1028-1035
31. Aghi M, Gaviani P, Henson JW et al (2005) Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 11:8600-8605
32. Giese A (2003) Glioma invasion - pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl 88:153-162
33. Brandes AA, Tosoni A, Cavallo G et al (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GINCO study. J Clin Oncol 24:4746-4753
34. Kamiryo T, Tada K, Shiraishi S et al (2004) Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2 -methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54:349-357